Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/AK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/AK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/AK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/AK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003103218 | Oral cavity | EOLP | actomyosin structure organization | 39/2218 | 196/18723 | 7.64e-04 | 6.12e-03 | 39 |
GO:0061572110 | Oral cavity | EOLP | actin filament bundle organization | 33/2218 | 161/18723 | 1.11e-03 | 8.11e-03 | 33 |
GO:004521619 | Oral cavity | EOLP | cell-cell junction organization | 39/2218 | 200/18723 | 1.14e-03 | 8.29e-03 | 39 |
GO:00182121 | Oral cavity | EOLP | peptidyl-tyrosine modification | 65/2218 | 378/18723 | 1.25e-03 | 9.02e-03 | 65 |
GO:00507301 | Oral cavity | EOLP | regulation of peptidyl-tyrosine phosphorylation | 48/2218 | 264/18723 | 1.61e-03 | 1.08e-02 | 48 |
GO:00181081 | Oral cavity | EOLP | peptidyl-tyrosine phosphorylation | 64/2218 | 375/18723 | 1.65e-03 | 1.09e-02 | 64 |
GO:0030038110 | Oral cavity | EOLP | contractile actin filament bundle assembly | 23/2218 | 106/18723 | 2.78e-03 | 1.66e-02 | 23 |
GO:0043149110 | Oral cavity | EOLP | stress fiber assembly | 23/2218 | 106/18723 | 2.78e-03 | 1.66e-02 | 23 |
GO:00480102 | Oral cavity | EOLP | vascular endothelial growth factor receptor signaling pathway | 15/2218 | 59/18723 | 3.01e-03 | 1.77e-02 | 15 |
GO:005149416 | Oral cavity | EOLP | negative regulation of cytoskeleton organization | 31/2218 | 163/18723 | 5.09e-03 | 2.67e-02 | 31 |
GO:00610971 | Oral cavity | EOLP | regulation of protein tyrosine kinase activity | 19/2218 | 90/18723 | 8.39e-03 | 3.91e-02 | 19 |
GO:000740910 | Oral cavity | EOLP | axonogenesis | 66/2218 | 418/18723 | 8.99e-03 | 4.13e-02 | 66 |
GO:0051492110 | Oral cavity | EOLP | regulation of stress fiber assembly | 19/2218 | 91/18723 | 9.46e-03 | 4.29e-02 | 19 |
GO:0032231110 | Oral cavity | EOLP | regulation of actin filament bundle assembly | 21/2218 | 105/18723 | 1.08e-02 | 4.80e-02 | 21 |
GO:006156414 | Oral cavity | EOLP | axon development | 72/2218 | 467/18723 | 1.14e-02 | 5.00e-02 | 72 |
GO:200123334 | Oral cavity | NEOLP | regulation of apoptotic signaling pathway | 94/2005 | 356/18723 | 4.19e-17 | 3.11e-14 | 94 |
GO:001603233 | Oral cavity | NEOLP | viral process | 101/2005 | 415/18723 | 1.08e-15 | 5.85e-13 | 101 |
GO:190290334 | Oral cavity | NEOLP | regulation of supramolecular fiber organization | 88/2005 | 383/18723 | 2.44e-12 | 4.83e-10 | 88 |
GO:004325432 | Oral cavity | NEOLP | regulation of protein-containing complex assembly | 95/2005 | 428/18723 | 2.76e-12 | 5.29e-10 | 95 |
GO:001905834 | Oral cavity | NEOLP | viral life cycle | 77/2005 | 317/18723 | 3.13e-12 | 5.82e-10 | 77 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa01240 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa012401 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0124021 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0124031 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AK2 | insertion | In_Frame_Ins | novel | c.499-1_499insCCCATGAAAGATGAC | p.Pro162_Asp166dup | p.P162_D166dup | P54819 | protein_coding | | | TCGA-AC-A3YI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
AK2 | insertion | Frame_Shift_Ins | novel | c.298_299insATAACACCTGCTTTGAGAA | p.Gly100AspfsTer20 | p.G100Dfs*20 | P54819 | protein_coding | | | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
AK2 | insertion | In_Frame_Ins | novel | c.499-1_499insCCCATGAAAGATGAC | p.Pro162_Asp166dup | p.P162_D166dup | P54819 | protein_coding | | | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
AK2 | SNV | Missense_Mutation | novel | c.98N>T | p.Pro33Leu | p.P33L | P54819 | protein_coding | deleterious(0.01) | benign(0.074) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AK2 | SNV | Missense_Mutation | novel | c.353N>T | p.Arg118Met | p.R118M | P54819 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AK2 | SNV | Missense_Mutation | rs770292274 | c.368N>G | p.Asp123Gly | p.D123G | P54819 | protein_coding | deleterious(0) | benign(0.399) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AK2 | SNV | Missense_Mutation | | c.231N>C | p.Glu77Asp | p.E77D | P54819 | protein_coding | tolerated(1) | benign(0.005) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AK2 | SNV | Missense_Mutation | rs370429097 | c.610N>T | p.Arg204Trp | p.R204W | P54819 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-D1-A16G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD |
AK2 | SNV | Missense_Mutation | rs765991265 | c.334G>A | p.Asp112Asn | p.D112N | P54819 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AK2 | SNV | Missense_Mutation | | c.524G>A | p.Arg175Gln | p.R175Q | P54819 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-BC-A10W-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Chemotherapy | unknown | PD |